Proactiveinvestors recommends

Additional Information

Market:	AIM
Sector:	Pharma & Biotech
EPIC:	APH
Latest Price:	29.75 (0.00%)
52-week High:	37.13
52-week Low:	26.25
Market Cap:	71.43M

1 year chart

1 day chart

Alliance Pharma plc Full Alliance Pharma plc profile here

Alliance Pharma plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development, marketing and distribution of pharmaceutical products. Its brands include Nu-Seals, Forceval, Hydromol, Deltacortril, Symmetrel, Syntocinon, Naseptin, Syntometrine, Synacthen and Slow-K.

Alliance Pharma’s second largest shareholder Nigel Wray ups stake to 13.38 pct

Friday, July 30, 2010

Alliance Pharma’s (LON:APH) second largest shareholder, Nigel Wray, has further increased his stake in the company by buying 3.15 million shares in the group yesterday, taking his holding to 31,119,995 shares, equivalent to 13.38 percent of the capital.
Chief executive John Dawson remains the largest shareholder with 46.68 million shares, or just over 20 percent.

Wray has been topping up his shareholding in the company over recent months, buying 1.9 million shares for 12.03 percent in the first week of July, buying a 0.8 million in June for 11.26 percent, and 0.75 million shares in May for 11.08 percent.

Alliance Pharma in February completed the acquisition of Cambridge Laboratories. The deal, which added 18 new prescription products to Alliance’s portfolio, is expected to be significantly earnings enhancing in the current financial year. The Buccastem and Timodine acquisition is also set to deliver full year benefits this year.

In an update ahead of its first half results, Alliance told investors at the beginning of July that it continues to benefit from strong trading with year-on-year revenues up 40 percent, excluding revenues from recently acquired products. Overall, in the six-months ended 30 June 2010, the company generated revenues of approximately £23.4 million, up more than £10 million from the first half of 2009.

Alliance highlighted that the sales from Deltacortril/enteric coated prednisolone continued to be strong during the period.

The new product portfolio, acquired from Cambridge Laboratories in 2010, was performing in line with the company’s expectations.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.